Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in HER2-negative Breast Cancer (PERIDENO)
NCT03532087Phase 2Withdrawn
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Feb 2018
- Primary completion
- Feb 2021
- Countries
- 1
01
Overview
A Phase 2 trial of denosumab in breast cancer, sponsored by Borstkanker Onderzoek Groep. Planned start Feb 2018; status: withdrawn.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03532087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03532087.